Pasithea Therapeutics Announces Successful Treatment of First Patients in the UK with Ketamine Infusion Therapy

2 years ago

– Pasithea Clinics commences IV ketamine infusion therapy in Knightsbridge, London, for the treatment of mental health disorders –MIAMI BEACH, Fla., Oct.…

Context Therapeutics® and Wisconsin Oncology Network Announce First Patient Dosed in Phase 2 Trial of ONA-XR in Metastatic Breast Cancer

2 years ago

Trial Will Evaluate Progesterone Receptor ONA-XR in Combination with Estrogen Receptor Antagonist to Determine Potential of Complete Hormone Blockade on…

Mydecine Reports Successful Synthesis of Novel Tryptamine Improving the Pharmaceutical Properties of Psilocin

2 years ago

Further strengthens the Company’s drug development pipeline of tryptamines by introducing novel psilocin analogues containing enhancements in safety and efficacy…

Werewolf Therapeutics to Present Data on its INDUKINE™ Product Candidates at the Society for Immunotherapy of Cancer Annual Meeting

2 years ago

Posters Detail Preclinical Data on the Company’s WTX-124 and WTX-330 Molecules for the Potential Treatment of CancerCAMBRIDGE, Mass., Oct. 27,…

VitalHub Announces Licensing Deal with Royal Berkshire NHS Foundation Trust

2 years ago

TORONTO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSX: VHI) is pleased to announce a…

InflaRx Announces Positive Data from Third Cohort of Phase IIa Open-Label Study with Vilobelimab in Pyoderma Gangraenosum

2 years ago

6 out of 7 patients (85.7%) showed clinical remission (PGA score ≤ 1) and closure of target ulcer in the…

AZSTARYS®, An Innovative ADHD Treatment Developed by KemPharm, to be Featured in a Poster Presentation at the 2021 Psych Congress

2 years ago

Pharmacokinetic data from two clinical studies of AZSTARYS demonstrated its rapid onset of action and long duration of effect CELEBRATION,…

Otonomy Announces Multiple Presentations at Neuroscience 2021 Meeting

2 years ago

Presentation of positive top-line clinical results for OTO-313 in tinnitus and OTO-413 in hearing loss Supportive preclinical data to be…

OraSure Technologies 2021 Third Quarter Earnings Conference Call Wednesday, November 3, 2021, 5:00 p.m. ET

2 years ago

BETHLEHEM, Pa., Oct. 27, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call…

Recro Enters Into Master Commercial Supply and Services Agreement With Otsuka

2 years ago

Agreement Establishes Recro as Commercial Supplier for Otsuka Deal Validates Recro’s “Second Source” Strategy of Supporting Commercial Programs as U.S.-Based…